Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
Wagner, F.F., Benajiba, L., Campbell, A.J., Weiwer, M., Sacher, J.R., Gale, J.P., Ross, L., Puissant, A., Alexe, G., Conway, A., Back, M., Pikman, Y., Galinsky, I., DeAngelo, D.J., Stone, R.M., Kaya, T., Shi, X., Robers, M.B., Machleidt, T., Wilkinson, J., Hermine, O., Kung, A., Stein, A.J., Lakshminarasimhan, D., Hemann, M.T., Scolnick, E., Zhang, Y.L., Pan, J.Q., Stegmaier, K., Holson, E.B.(2018) Sci Transl Med 10
- PubMed: 29515000 
- DOI: 10.1126/scitranslmed.aam8460
- Primary Citation of Related Structures:  
5KPK, 5KPL, 5KPM, 5T31 - PubMed Abstract: 
Glycogen synthase kinase 3 (GSK3), a key regulatory kinase in the wingless-type MMTV integration site family (WNT) pathway, is a therapeutic target of interest in many diseases. Although dual GSK3α/β inhibitors have entered clinical trials, none has successfully translated to clinical application ...